Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhGH + PRP intra-articular injections for ankle or knee arthritis
ACTRN12625000243415Phase 3Not yet recruiting
- Sponsor
- Integrant
- Start
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of somatropin and platelet-rich plasma in ankle osteoarthritis and knee osteoarthritis (OA) (2 arms), sponsored by Integrant. Primary endpoints: Ankle functionality and quality of life and Knee functionality and quality of life. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
somatropinplatelet-rich plasma
03
Conditions
ankle osteoarthritisknee osteoarthritis (OA)
Beyond the preview
Go deeper on ACTRN12625000243415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000243415.